ADORA2A-AS1

Across TCGA pan-cancer cohorts, ADORA2A-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ADORA2A-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADORA2A-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADORA2A-AS1 is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

KIRC, KIRP, and KICH are the cancer types where ADORA2A-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADORA2A-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+1.129	<.001	12	view →
KIRP	Male	III,IV	−1.974	<.001	8	view →
KICH	Male	II,III,IV	−1.816	<.001	7	view →
THCA	All	All	−0.092	<.001	7	view →
BRCA	All	IV	+0.325	.001	6	view →
CHOL	Female	All	−3.500	<.001	5	view →
LUSC	Female	All	−0.212	.003	3	view →
UCEC	All	All	−0.137	<.001	2	view →
PRAD	All	All	−0.078	.014	2	view →
LIHC	Male	All	+0.640	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ADORA2A-AS1–KIRC

Open the KIRC breakdown →